Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

Filippi, A.R.; Bar, J.; Chouaid, C.; Christoph, D.C.; Field, J.K.; Fietkau, R.; Garassino, M.C.; Garrido, P.; Haakensen, V.D.; Kao, S.; Markman, B.; McDonald, F.; Mornex, F.; Moskovitz, M.; Peters, S.; Sibille, A.; Siva, S.; van den Heuvel, M.; Vercauter, P.; Anand, S.; Chander, P.; Licour, M.; de Lima, A.R.; Qiao, Y.; Girard, N.

doi:10.1016/j.esmoop.2024.103464

ESMO Open

2024

DOI: 10.1016/j.esmoop.2024.103464

|View full text |Cite

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

A.R. Filippi,

J. Bar,

C. Chouaid

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 29 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy

Damhuis,

Bahce,

Senan

2024

Clinical Lung Cancer

View full text Add to dashboard Cite

Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy

Damhuis,

Bahce,

Senan

2024

Clinical Lung Cancer

View full text Add to dashboard Cite

Assessment of NSCLC disease burden: A survival model-based meta-analysis study

Kudryashova,

Shulgin,

Katuninks

et al. 2024

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

Can We Offset Local Recurrence in Locally Advanced Non–Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes

Owen,

Chapman

2024

JCO

View full text Add to dashboard Cite

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

Cited by 4 publications

References 29 publications

Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy

Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy

Assessment of NSCLC disease burden: A survival model-based meta-analysis study

Can We Offset Local Recurrence in Locally Advanced Non–Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes

Contact Info

Product

Resources

About